Skip to main content
SAB Biotherapeutics, Inc. logo

SAB Biotherapeutics, Inc. — Investor Relations & Filings

Ticker · SABS ISIN · US0891152086 US Manufacturing
Open in API
Filings indexed 398 across all filing types
Latest filing 2023-11-28 Director's Dealing
Country US United States of America
Listing US SABS

About SAB Biotherapeutics, Inc.

https://www.sab.bio/

SAB Biotherapeutics is a clinical-stage biopharmaceutical company advancing a novel class of immunotherapies. The company's proprietary platform produces targeted, high-potency, fully human polyclonal antibodies without the need for human donors. This technology utilizes transgenic cattle to generate natural human antibodies in response to specific disease targets. The company's lead product candidate, SAB-142, is a disease-modifying immunotherapy being developed to delay the onset and progression of Type 1 Diabetes (T1D) by addressing the underlying autoimmune cause. SAB's development pipeline also includes programs targeting infectious diseases, such as severe influenza and antibiotic resistance.

Recent filings

Filing Released Lang Actions
4
Director's Dealing
2023-11-28 English
4
Director's Dealing
2023-11-28 English
Capital/Financing Update 2023
Capital/Financing Update Classification · 95% confidence The document is a correspondence letter addressed to the SEC regarding a Registration Statement on Form S-3. It requests acceleration of the effective date of the Registration Statement. The content is related to a capital raising or securities offering process, specifically a registration statement filing under the Securities Act. The document is short (1085 characters) and is a formal request rather than a report or financial statement. This fits the category of Capital/Financing Update (CAP), which covers updates on company fundraising and financing activities.
2023-11-24 English
8-K
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is a Form 8-K Current Report filed with the SEC, dated November 22, 2023. It reports on a Special Meeting of Stockholders where amendments to the Articles of Incorporation were approved, specifically increasing the authorized shares of common stock. It also includes the official voting results of the stockholder proposals. The document includes a Certificate of Amendment as an exhibit and detailed voting results. This type of filing is a regulatory announcement of corporate governance changes and voting results, not a full annual or quarterly report, nor a proxy statement or remuneration report. The key content is the submission of matters to a vote and the official voting results, which aligns with the category "Declaration of Voting Results & Voting Rights Announcements (DVA)". The document length is sufficient and contains detailed voting data, confirming it is not merely an announcement of a report but the actual voting results filing.
2023-11-22 English
3
Director's Dealing
2023-11-22 English
8-K
Board/Management Information Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a Current Report used to announce major events that shareholders should know about. The content specifically details the appointment of a new director to the company's board, including biographical information and related disclosures. There is no financial data or earnings information, nor is it an annual or quarterly report. The key section is Item 5.02, which relates to departure or appointment of directors or officers. This matches the definition of Board/Management Information (MANG). The document length is 6670 characters, which is sufficient to contain detailed information about the director appointment. Therefore, the correct classification is MANG with high confidence.
2023-11-20 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.